300871 回盛生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)3.50813.943-1.3591.1003.336
总资产报酬率 ROA (%)2.4838.406-0.6730.5631.839
投入资产回报率 ROIC (%)2.8079.571-0.7760.6602.090

边际利润分析
销售毛利率 (%)35.51230.98816.33420.91622.032
营业利润率 (%)19.05917.277-2.4231.4795.783
息税前利润/营业总收入 (%)18.80017.9370.9593.6156.922
净利润/营业总收入 (%)17.07615.077-1.6471.6465.153

收益指标分析
经营活动净收益/利润总额(%)108.27892.522101.72527.630105.469
价值变动净收益/利润总额(%)-8.5573.49653.335203.95212.361
营业外收支净额/利润总额(%)0.008-0.631-0.386-21.231-4.316

偿债能力分析
流动比率 (X)1.9271.7651.4221.6211.679
速动比率 (X)1.5731.4031.1531.3281.432
资产负债率 (%)30.17827.32751.39849.27648.432
带息债务/全部投入资本 (%)20.11815.31142.45637.23236.723
股东权益/带息债务 (%)386.408538.977129.269159.755164.582
股东权益/负债合计 (%)230.002264.38094.069102.940106.476
利息保障倍数 (X)-72.09423.3470.2841.5095.022

营运能力分析
应收账款周转天数 (天)82.19181.705103.004115.881100.276
存货周转天数 (天)82.76080.05985.46595.45697.174